American Society of Cataract and Refractive Surgery Meeting

American Society of Cataract and Refractive Surgery Meeting

April 28, 2014
1 min read

Test designed to detect genetic mutations in patients undergoing LASIK

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Avellino Lab USA is launching the Avellino DNA Dual Test for LASIK Safety, which can detect genetic mutations that cause postoperative complications, according to a news release.

The test, which is being introduced at the American Society of Cataract and Refractive Surgery meeting, is designed to detect Avellino corneal dystrophy (ACD) and granular corneal dystrophy type 1 (GCD1).

GCD1 features small translucent granules that form slowly in the layers of the cornea. Patients with GCD1 who undergo LASIK, LASEK or PRK are at an elevated risk of blindness.

The test can pinpoint GCD1 or ACD, also known as GCD2, in patients scheduled for LASIK and help them avoid postoperative visual complications.

The test involves a mouth swab to determine if a patient carries the GCD1 or the GCD2 gene mutation. The ophthalmologist takes 10 swipes from the inside of each cheek to get a suitable sample that is sent to Avellino Lab USA, a certified molecular diagnostic testing lab. Results are sent to the physician within 24 to 48 hours.